SLC5A2 and type 2 diabetes mellitus: Canagliflozin (Cana), a sodium-glucose cotransporter 2 inhibitor (SGLT2i), has been used as a therapeutic intervention for type 2 diabetes mellitus (T2DM), serving to reduce glucose reabsorption in the kidneys and augment glucose excretion via urine (1).